NCT02710643 2022-06-21
FIL_MIRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
Clinical Trials
6 trialsNCT01190449 2021-08-18
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00742144 2017-11-17
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1 Completed
NCT00092274 2015-04-21
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
GlaxoSmithKline
Phase 1/2 Withdrawn
NCT01397591 2014-07-30
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00494780 2014-07-11
MUNIN
GlaxoSmithKline
Phase 2 Completed